论文部分内容阅读
目的探讨西酞普兰治疗2型糖尿病合并抑郁症的疗效。方法选取70例2型糖尿病合并抑郁症患者,随即分为西肽普兰组(实验组)35例、对照组35例,治疗12周,采用糖化血红蛋白(HBA1C)、空腹血糖变异系数(CV-FPG)评价血糖控制情况,汉密尔顿抑郁量表(HAMD)、糖尿病生活质量量表(DQOL)评定药物疗效波动。结果治疗12周后,实验组HBA1C下降明显(7.2±0.6vs8.0±1.1,P<0.05)、CV-FPG较对照组小(10.7±2.3vs15.9±2.9,P<0.05),生活质量改善优于实验组(HAMD8.12±2.68vs14.66±3.73,DQOL89±8vs98±10,P<0.05)。结论西肽普兰能促进2型糖尿病合并抑郁症患者血糖平稳下降,改善患者抑郁症状,提高生活质量。
Objective To investigate the efficacy of citalopram in the treatment of type 2 diabetes with depression. Methods Seventy-two patients with type 2 diabetes mellitus and depression were divided into three groups: 35 patients in the experimental group and 35 patients in the control group for 12 weeks. HbA1c, CV-FPG ) Evaluated glycemic control, Hamilton Depression Rating Scale (HAMD), and Diabetes Quality of Life Scale (DQOL) to assess drug efficacy fluctuations. Results After 12 weeks of treatment, HBA1C in experimental group decreased significantly (7.2 ± 0.6 vs 8.0 ± 1.1, P <0.05), CV-FPG was smaller (10.7 ± 2.3 vs 15.9 ± 2.9, P <0.05) Better than the experimental group (HAMD8.12 ± 2.68vs14.66 ± 3.73, DQOL89 ± 8vs98 ± 10, P <0.05). Conclusion Cetuximab can promote the steady decline of blood glucose in patients with type 2 diabetes mellitus and depression, improve the symptoms of depression and improve the quality of life.